[New aspects of rabies control]. [PDF]
Bourhy H, de Melo GD, Tarantola A.
europepmc +1 more source
[Post-exposure prophylaxis against Ebola virus: arguments for expanding the role of monoclonal antibodies in a context of limited access]. [PDF]
Potet J +4 more
europepmc +1 more source
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)]. [PDF]
Gligorov J +40 more
europepmc +1 more source
[Bullous mycosis fungoides-clinical indicator for an aggressive course of disease]. [PDF]
Gerdes AL +6 more
europepmc +1 more source
Compound Optimal Designs for Percentile Estimation in Dose-Response Models with Restricted Design Intervals [PDF]
In dose-response studies, the dose range is often restricted due to ethics concerns over drug toxicity and/or efficacy, particularly when human subjects are involved.
Zhu, Wei +2 more
core
[Risk perception of COVID-19 pandemic among health care providers: qualitative study conducted at the King Baudoin Hospital in Guédiawaye, the first hospital faced with managing a community-acquired COVID-19 case in Senegal]. [PDF]
Sougou NM, Diouf JB, Diallo AA, Seck I.
europepmc +1 more source
Evoluzione terapeutica: tradurre l’innovazione farmacologica in benefici tangibili per le persone con emofilia A. Una prospettiva multi-stakeholder. [PDF]
Di Minno MND +7 more
europepmc +1 more source

